Synergo Rite

RF chemo-hypertermic NMIBC treatment

Bladder cancer is the 4th most common malignancy among men, and the 13th most frequent among women.

More than 330,000 new cases of bladder cancer are diagnosed worldwide every year. Approximately 75% of these cases are non-muscle invasive disease originating in the bladder wall lining (urothelium).

This type of tumour tends to recur, mostly as non-muscle invasive cancer, despite treatment.

A tumour that penetrates more deeply into the muscular layer of the urinary bladder is called “invasive” bladder cancer.

Synergo® is an advanced, minimally invasive technology for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

The treatment is based on controlled hyperthermia (through RF non-ionising microwave radiation) of the bladder walls, along with instillations of the bladder with a chemotherapeutic substance (chemohyperthermia). The patient is treated on an outpatient basis in a series of weekly one-hour treatments with no need for anaesthesia.

Synergo® thermochemotherapy System is a computer-embedded intravesical irrigation system combined with an energy-delivering unit.

The System includes an RF generator that delivers radio-frequency energy at 915 MHz (the lower limit of microwave electromagnetism), a drug circulating unit, and a microprocessor with application specific software.
The user interface consists of a computer, monitor with touch screen, and barcode reader. The software monitors and records treatment parameters in real-time during the treatment session.
The Synergo® catheter is used for the drug intravesical instillation. The catheter is equipped with an integrated miniaturised RF antenna that radiates the bladder walls and 5 thermocouples (miniature thermometers) that monitor the bladder tissue temperature during the treatment.


The Synergo® catheter performs three main functions:

  1. Radiofrequency radiation (local, non-ionising) of the bladder walls, also uniformly heating them by means of a small RF-emitting antenna.
  2. Temperature monitoring by sensitive thermocouples in several locations on the bladder wall and urethra.
  3. Circulation of the cooled chemotherapeutic drug into and out of the bladder.

The use of Synergo® was approved by the European Standard Authorities (CE) in 2001.

Since then the treatment has become available in many leading medical centres.

So far, thousands of patients have been treated with Synergo® worldwide and many studies (including randomised trials) have been conducted over the years.

The Synergo® technology has been proven safe and efficacious in numerous routine treatment studies and clinical trials that have been published since 1995.


From January, 1st 2019 MOSS S.p.A. is the Nation Distributor of the Technology in Italy.


Medical Enterprises Europe B.V.

Amsterdamseweg 147A

1182GT, Amstelveen

The Netherlands